Nevada Salesman, His Domestic Partner, And Reno Businessman Indicted For Conspiring To Defraud The IRS

Saud Alessa, Jeffrey Bowen, and Jackie Hayes

According to the indictment, Bowen was the President and owner of a vacuum cleaner distributing company in Reno, Nevada. Alessa worked for Bowen’s company on sales teams from 1998 to 2006. During those years, Alessa allegedly accrued over $200,000 in unpaid federal income tax. In 2006, the IRS began attempting to collect Alessa’s outstanding tax liabilities. Alessa allegedly did not voluntarily pay any of his outstanding debt to the IRS, and in 2013, Alessa filed a bankruptcy petition reporting that he owed a federal tax debt of $503,821, to the IRS.

The indictment charges that between 2010 and 2013 Alessa, Alessa’s longtime domestic partner Hayes, and Bowen conspired to conceal Alessa’s business activity and income from the IRS. Alessa’s commissions and other earned income earned were allegedly recorded in Bowen’s company’s books in Hayes’s name and paid to Hayes instead of Alessa. Alessa, Bowen, and Hayes allegedly filed fraudulent documents with the IRS that disguised the commissions and other income earned by Alessa as income earned by Hayes. In order to further the scheme, the co-conspirators allegedly made false and misleading statements to the IRS, the United States Bankruptcy Court, and the United States Trustee’s office to convince the authorities that Alessa had no business activity and no source of income that could be used to pay Alessa’s outstanding tax debt to the IRS.

Moar

https://www.justice.gov/usao-nv/pr/nevada-salesman-his-domestic-partner-and-reno-businessman-indicted-conspiring-defraud-irs

San Diego GenomeDx A Genetic Testing Company Agrees to Pay $1.99 Million to Resolve Allegations of False Claims to Medicare for Medically Unnecessary Tests

SAN DIEGO – GenomeDx Biosciences Corp. (“GenomeDx”) has agreed to pay $1.99 million to resolve allegations that it violated the False Claims Act, 31 U.S.C. §§ 3729 et seq., by submitting false claims to Medicare for its “Decipher®” post-operative genetic test for prostate cancer patients.

GenomeDx is a genomic testing company with operations based in San Diego and headquarters in Vancouver, British Columbia.

The United States alleged that GenomeDx submitted claims to Medicare between September 2015 and June 2017 for the Decipher test that were not medically reasonable and necessary because the prostate cancer patients did not have risk factors necessitating the test,

namely pathological stage T2 disease with a positive surgical margin, pathological stage T3 disease, or rising Prostate-Specific Antigen (“PSA”) levels after an initial PSA nadir.

“The Department of Justice is committed to ensuring that Medicare patients only receive laboratory testing that is reasonable and necessary for the individual patient,” said Assistant Attorney General Joseph A. Hunt. “Medically unnecessary and unproven testing increases costs for federal health care programs and is not in the interest of patients.”

https://www.justice.gov/usao-sdca/pr/san-diego-genetic-testing-company-agrees-pay-199-million-resolve-allegations-false

>>51352811

T3, T2…

>>5135387